PHKA1

Across TCGA pan-cancer cohorts, PHKA1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PHKA1 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PHKA1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PHKA1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where PHKA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.234	0.904	<.001	21	view →
LUAD	DFS	Tertile	All	0.666	0.878	.003	14	view →
UCEC	DFS	Median	All	0.925	0.779	.012	12	view →
CCRCC	OS	Median	IV	0.139	0.664	.039	2	view →
GBM	DFS	Tertile	All	0.874	0.722	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PHKA1–PDAC (DFS)

Open the PDAC breakdown →